1,721,038 research outputs found
From mesenchymal stem/stromal cells to cell products: pharmaceutical development of secretome as new biological medicinal product
No full textSilk-based Drug Delivery Systems
No full textSilk proteins show excellent biocompatibility, controllable biodegradability and non-immunogenicity, and as such are studied extensively worldwide for biomedical applications. In particular, there is increasing interest in their use for drug delivery systems. This focussed book on silk proteins for drug delivery systems, delves into a key emerging area to outline the concepts and define the field.
Covering spider silk and silk worm cocoons, the editors elucidate the extraction, structure and properties of silk sericin and silk fibroin. Showing how these proteins are employed in micro and nano drug delivery systems, their use in pre-clinical and clinical trials, and closing with chapter on sustainability- driven innovation in the pharma industry, this book is ideal for graduates and researchers in biomaterials science and pharmaceutical science
Auricchio F, Bari E, Conti M, Perteghella S, Scocozza F, Sorlini M, Torre ML. Scaffold per la rigenerazione tissutale, in particolare per la rigenerazione ossea, e relativo metodo di fabbricazione.
No full textMesenchymal stem/stromal cell secretome for lung regeneration: The long way through “pharmaceuticalization” for the best formulation.
No full textPulmonary acute and chronic diseases, such as chronic obstructive pulmonary disease, pulmonary fibrosis and pulmonary hypertension, are considered to be major health issues worldwide. Cellular therapies with Mesenchymal Stem Cells (MSCs) offer a new therapeutic approach for chronic and acute lung diseases related to their anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties. Such therapeutic effects can be attributed to MSC-secretome, made of free soluble proteins and extracellular vesicles (EVs). This review summarizes the recent findings related to the efficacy and safety of MSC-derived products in pre-clinical models of lung diseases, pointing out the biologically active substances contained into MSC-secretome and their mechanisms involved in tissue regeneration. A perspective view is then provided about the missing steps required for the secretome “pharmaceuticalization” into a high quality, safe and effective medicinal product, as well as the formulation strategies required for EV non-invasive route of administration, such as inhalation
Scaffold for tissue regeneration, particularly for bone regeneration, and manufacturing method thereof.
No full textAssociation of silk sericin and platelet lysate: Premises for the formulation of wound healing active medications
No full textSilk sericin (SS), a globular and water-soluble protein, showed to in vitro sustain the proliferation of different mammalian cell lines, and to in vitro protect them from the oxidative stress because of its free-radical-scavenging activity. Also, platelet-derived products, such as platelet gel, platelet rich plasma or platelet lysate (PL) are used in cell cultures as a serum substitute due to their great content of growth factors. In the clinical practice, both SS and PL were employed for various reparative treatments and showed to sustain the wound repair process regulating fibroblast recruitment, migration, proliferation and differentiation. For these reasons, the combination of PL and SS could lead to effective and innovative products, either for the ex vivo cell expansion, or for the production of active wound healing advanced medications
From mesenchymal stem/stromal cells to cell products: pharmaceutical evelompment of secretome as new biological medicinal product
No full textMembrane vesicles secreted by mesenchymal stem cells for drug delivery in musculoskeletal regeneration
No full textScaffold for tissue regeneration, particularly for bone regeneration, and manufacturing method thereof.
No full textAnti-angiogenic activity of uncoated- and N,O-carboxymethyl-chitosan surface modified-Gelucire® 50/13 based solid lipid nanoparticles for oral delivery of curcumin.
Full text linkThe co-administration of anti-tumor and anti-angiogenesis agents represents a well-established strategy for
cancer treatment. However, the clinical use of this “combined therapy” approach showed several limitations
probably due to the inability of most angiogenic inhibitors to target tumor vessels. Herein, we evaluated the
in vitro angiogenesis effects of N,O-carboxymethyl chitosan (N,O-CMCS) surface modified curcumin (CUR)-
loaded solid lipid nanoparticles (SLN) intended for CUR oral administration. For this purpose, SLN formulations
based on Gelucire® 50/13 were prepared and characterized for their physicochemical properties. From stability
tests such SLN resulted useful to protect CUR from oxidative and hydrolytic degradation for a long period at 4 °C.
Moreover, N,O-CMCS-c-CUR SLN (F4) displayed enhanced cytocompatibility with Caco-2 cells. Data from angiogenesis
studies showed that the CUR-unloaded and surface unmodified SLN (b-SLN, F1) possess anti-angiogenic
activity and, moreover, due to the features of the coating polysaccharide, F4 may constitute an antiangiogenic
delivery platform for CUR oral delivery and such delivery system seems promising in vascular angiogenesis
inhibition
- …
